ClinicalTrials.gg
CompletedNCT01458171Updated Apr 9, 2013Results posted

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

A Phase 3 interventional study of Immune globulin subcutaneous (Human) in Primary Immune Deficiency Disorder, sponsored by CSL Behring. Completed at 9 sites in Japan. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2013-04-09.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
20th of 26
23 · median 45
Started
2011
with 6 others
Phase 3
18 of 27
2 open now
Registered
14th of 27
by date
Lead sponsor
2 of 27
CSL Behring

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 18 in phase 3, and was the 14th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).

03

Conditions studied

  • Primary Immune Deficiency Disorder

Keywords

  • Immune globulin subcutaneous
  • SCIG
  • Primary immunodeficiency
  • PID
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have participated in study ZLB06_002CR and who have tolerated IgPro20 well.
  • Written by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years at the time of obtaining informed consent), as far as possible.

Exclusion criteria

Exclusion Criteria:

  • Ongoing serious bacterial infections (SBIs) (pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of the first infusion.
  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (known total urine protein concentration >0.2 g/L or urine protein ++ by dipstick).
  • Pregnancy or nursing mother.
  • Participation in a study with an medicinal product (IMP) within 3 months prior to enrollment except for ZLB06_002CR.
  • Subjects who are planning to donate blood during the study.
  • Re-entry of subjects previously participating in the current follow-up study.
  • Known or suspected antibodies to the IMP, or to of the IMP.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    IgPro20

    Biological: Immune globulin subcutaneous (Human)

Interventions

  • IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).

    Also known as: Hizentra

06

What researchers measure

Primary outcomes

  1. Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion

    The rate was calculated by counting all newly developed or worsened AEs within a subject and dividing by the total number of IgPro20 infusions administered to this subject. Subsequently, the median of these individual AE rates per infusion was calculated. AE rates were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).

    Time frame: 24 weeks

Secondary outcomes

  1. Overall Rate of AEs Per Infusion

    The rate was calculated by counting all newly developed or worsened AEs during the treatment period in all subjects and dividing the total number of AEs by the total number of IgPro20 infusions administered. In addition, individual AEs were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]). The AE rates per infusion by severity and causal relationship to study medication were calculated by dividing the number of AEs in each category by the total number of IgPro20 infusions.

    Time frame: 24 weeks

  2. Number of Subjects With Newly Developing or Worsening AEs

    Number of subjects with AEs, overall and classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).

    Time frame: 24 weeks

  3. Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good'

    Subjects assessed their overall perception of local tolerability at the infusion site throughout the study in the subject diary within a time window of 24 h to 72 h after the end of the latest infusion by assessing it as "very good", "good", "fair", or "poor". The reported percentage represents the percentage of subjects with local tolerability assessments of "very good" or "good" at any given study infusion.

    Time frame: 24 to 72 hours after infusion

  4. IgG Trough Level

    Serum IgG trough levels at the completion visit compared to the baseline visit of the follow-up study. IgG trough levels at baseline, at the completion visit, and the change from baseline to the completion visit are shown

    Time frame: 24 weeks

  5. Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)

    SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess. The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the FAS and PPS and adjusted to 365 days.

    Time frame: 24 weeks

  6. Number of Infection Episodes (Serious and Non-serious)

    Time frame: 24 weeks

  7. Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.

    Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections.

    Time frame: 24 weeks

  8. Number of Days of Hospitalization Due to Infections.

    Median number of days of hospitalization due to infections.

    Time frame: 24 weeks

  9. Duration of Use of Antibiotics for Infection Prophylaxis and Treatment

    Median number of days of use of antibiotics for infection prophylaxis and/or treatment

    Time frame: 24 weeks

Other outcomes

  1. Rate of Infection Episodes (Serious and Non-serious)

    The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the FAS population and the PPS population and adjusted to 365 days.

    Time frame: 24 weeks

07

Results

Posted Apr 9, 2013

Participant flow

This multicenter study enrolled subjects at nine study centers in Japan who had participated in the preceding pivotal study ZLB06_002CR (CT.gov identifier: NCT01199705).

Participant flow — Overall Study
MilestoneIgPro20
Started23
Completed22
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryMedian of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion

The rate was calculated by counting all newly developed or worsened AEs within a subject and dividing by the total number of IgPro20 infusions administered to this subject. Subsequently, the median of these individual AE rates per infusion was calculated. AE rates were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).

Time frame:
24 weeks
Reported as:
Median · AEs per infusion
Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion
AEs per infusionIgPro20
All AEs0.167 (0 to 1.71)
Mild AEs0.125 (0 to 1.71)
Moderate AEs0 (0 to 0.04)
Severe AEs0 (0 to 1.00)
Not related or unlikely related AEs0.125 (0 to 0.75)
At least possibly related AEs0 (0 to 1.00)
SecondaryOverall Rate of AEs Per Infusion

The rate was calculated by counting all newly developed or worsened AEs during the treatment period in all subjects and dividing the total number of AEs by the total number of IgPro20 infusions administered. In addition, individual AEs were classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]). The AE rates per infusion by severity and causal relationship to study medication were calculated by dividing the number of AEs in each category by the total number of IgPro20 infusions.

Time frame:
24 weeks
Reported as:
Number · AEs per infusion
Overall Rate of AEs Per Infusion
AEs per infusionIgPro20
All AEs0.346
Mild AEs0.342
Moderate AEs0.002
Severe AEs0.002
Not related or unlikely related AEs0.210
At least possibly related AEs0.136
SecondaryNumber of Subjects With Newly Developing or Worsening AEs

Number of subjects with AEs, overall and classified (i) by severity (mild, moderate, severe) and (ii) by causal relationship to study medication (not related or unlikely related; at least possibly related \[i.e., possibly related, probably related, or related\]).

Time frame:
24 weeks
Reported as:
Number · participants
Number of Subjects With Newly Developing or Worsening AEs
participantsIgPro20
All AEs22
Mild AEs21
Moderate AEs1
Severe AEs1
Not related or unlikely related12
At least possibly related10
SecondaryPercentage of Infusions With Subject-assessed Tolerability of at Least 'Good'

Subjects assessed their overall perception of local tolerability at the infusion site throughout the study in the subject diary within a time window of 24 h to 72 h after the end of the latest infusion by assessing it as "very good", "good", "fair", or "poor". The reported percentage represents the percentage of subjects with local tolerability assessments of "very good" or "good" at any given study infusion.

Time frame:
24 to 72 hours after infusion
Reported as:
Number · percentage of infusions
Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good'
percentage of infusionsIgPro20
Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good'85.4
SecondaryIgG Trough Level

Serum IgG trough levels at the completion visit compared to the baseline visit of the follow-up study. IgG trough levels at baseline, at the completion visit, and the change from baseline to the completion visit are shown

Time frame:
24 weeks
Reported as:
Mean · g/L
IgG Trough Level
g/LIgPro20 - FASIgPro20 - PPS
Baseline7.469 ± 1.39437.586 ± 1.3363
Completion visit8.914 ± 4.05028.227 ± 1.5458
Change from baseline to the completion vist1.445 ± 3.43790.642 ± 0.7687
SecondaryAnnualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)

SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess. The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the FAS and PPS and adjusted to 365 days.

Time frame:
24 weeks
Reported as:
Number · SBIs per subject year
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)
SBIs per subject yearIgPro20 - FASIgPro20 - PPS
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)0.000.00
Statistical analysis
  • IgPro20 - FAS · Annualized rate: 0.00
  • IgPro20 - PPS · Annualized rate: 0.00
SecondaryNumber of Infection Episodes (Serious and Non-serious)
Time frame:
24 weeks
Reported as:
Number · infection episodes
Number of Infection Episodes (Serious and Non-serious)
infection episodesIgPro20 - FASIgPro20 - PPS
Number of Infection Episodes (Serious and Non-serious)4338
SecondaryNumber of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.

Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections.

Time frame:
24 weeks
Reported as:
Median · days
Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.
daysIgPro20 - FASIgPro20 - PPS
Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections.0 (0 to 12)0 (0 to 9)
SecondaryNumber of Days of Hospitalization Due to Infections.

Median number of days of hospitalization due to infections.

Time frame:
24 weeks
Reported as:
Median · days
Number of Days of Hospitalization Due to Infections.
daysIgPro20 - FASIgPro20 - PPS
Number of Days of Hospitalization Due to Infections.0 (0 to 11)0 (0 to 0)
SecondaryDuration of Use of Antibiotics for Infection Prophylaxis and Treatment

Median number of days of use of antibiotics for infection prophylaxis and/or treatment

Time frame:
24 weeks
Reported as:
Median · days
Duration of Use of Antibiotics for Infection Prophylaxis and Treatment
daysIgPro20 - FASIgPro20 - PPS
Duration of Use of Antibiotics for Infection Prophylaxis and Treatment91.5 (6 to 170)154.0 (6 to 170)
Other pre-specifiedRate of Infection Episodes (Serious and Non-serious)

The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the FAS population and the PPS population and adjusted to 365 days.

Time frame:
24 weeks
Reported as:
Number · infection episodes per subject year
Rate of Infection Episodes (Serious and Non-serious)
infection episodes per subject yearIgPro20 - FASIgPro20 - PPS
Rate of Infection Episodes (Serious and Non-serious)4.204.32

Adverse events

Collected over For the duration of the study, that is, 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20—1/23 (4.3%)20/23 (87%)
Most frequent serious events
Most frequent serious events
EventIgPro20
EncephalitisNervous system disorders1/23
Most frequent other events
Showing 10 of 16
Most frequent other events
EventIgPro20
NasopharyngitisInfections and infestations6/23
EczemaSkin and subcutaneous tissue disorders6/23
Injection site painGeneral disorders5/23
Upper respiratory tract infectionInfections and infestations5/23
Dental cariesGastrointestinal disorders4/23
Arthropod biteInjury, poisoning and procedural complications3/23
HeadacheNervous system disorders3/23
Injection site indurationGeneral disorders2/23
PyrexiaGeneral disorders2/23
BronchitisInfections and infestations2/23

Baseline characteristics

Age Continuous
Age Continuous(years)IgPro20
Mean20.8 ± 13.68
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20
Female9
Male14
08

Study locations

9 sites
  • Study site
    Nagoya city, Aichi Pref. 466-8560, Japan
  • Study site
    Chiba city, Chiba Pref. 260-8677, Japan
  • Study site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Study site
    Gifu city, Gifu Pref. 502-8558, Japan
  • Study site
    Sapporo city, Hokkaido 060-8648, Japan
  • Study site
    Moriguchi city, Osaka 570-8507, Japan
  • Study site
    Koshigaya city, Saitama Pref. 343-8555, Japan
  • Study site
    Tokorozawa city, Saitama Pref. 359-8513, Japan
  • Study site
    Bunkyo-ku, Tokyo Metropolitan 113-8519, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2011
First posted
Oct 24, 2011
Start
Apr 2011
Primary completionActual
Feb 2012
CompletionActual
Apr 2012
Results first posted
Apr 9, 2013
Last update
Apr 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01458171
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Apr 2011
Primary completion
Feb 2012
Completion
Apr 2012
Results posted
Apr 9, 2013
Last update
Apr 9, 2013

Study contacts

Midori Kobayashi
study director · CSL Behring K.K.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion